DOI: 10.1128/JCM.01602-10
Article Figures & Data
Figures
- Fig. 1.
HROC curves. (A) TP level I individuals (with candidemia) versus TN at-risk patients (49 studies). (B) TP level II individuals (with proven/probable IC) versus TN at-risk patients (17 studies). (C) TP level III individuals (with proven/probable/possible IC) versus TN at-risk patients (20 studies). In each panel, the shaded square marks the summary point. Open circles, study estimates; solid lines, HSROC curves; dashed lines, 95% confidence regions; dotted lines, 95% prediction regions.
Tables
- Table 1.
Results of the diagnostic meta-analyses (hierarchical summary receiver operating characteristic curves)a
Comparison with TN at-risk patients (no. of studies) Illustration Sensitivity Specificity DOR Likelihood ratio Positive Negative TP I individuals (with candidemia) Allb (49) Fig. 1A; Fig. S3 in the supplemental material 0.95 (0.88–0.98) 0.92 (0.88–0.95) 229.1 (85–617.3) 12.3 (7.9–19.3) 0.05 (0.02–0.14) Yr, ≥2000b,c (27) Fig. S4A in the supplemental material 0.93 (0.91–0.97) 0.94 (0.89–0.97) 195.7 (70.9–540.4) 15.4 (9–26.4) 0.08 (0.03–0.21) Subgroup analysis: whole blood; rRNA or p450 gene target; detection limit, ≤10 CFU/ml; SeptiFast excluded (23) Fig. S5 in the supplemental material 0.98 (0.85–1) 0.90 (0.82–0.85) 394.9 (56.4–2,765.4) 10.2 (5.5–18.9) 0.03 (0.004–0.18) TP II individuals (with proven/probable IC) Allb (17) Fig. 1B 0.93 (0.82–0.98) 0.95 (0.87–0.98) 251.9 (57.4–1,106) 18.2 (7–47.2) 0.07 (0.03–0.2) Yr, ≥2000 (8) Fig. S4B in the supplemental material 0.87 (0.70–0.95) 0.96 (0.92–0.98) 178.9 (51.1–626.8) 24.3 (11.3–52.4) 0.14 (0.05–0.33) TP III individuals (with proven/probable/possible IC) All (20) Fig. 1C 0.73 (0.58–0.83) 0.91 (0.82–0.96) 26.9 (10.5–69.2) 8.1 (4–16.5) 0.3 (0.9–0.48) Yr, ≥2000 (11) Fig. S4C in the supplemental material 0.71 (0.52–0.85) 0.95 (0.92–0.97) 47.3 (16.9–132.9) 14.4 (8–25.2) 0.3 (0.17–0.55)
Supplemental material
Files in this Data Supplement:
- Supplemental file 1
-
Tables S1 (QUADAS items assessed, adapted for the current review), S2 (Study characteristics), and S3 and S4 (Study design
and methods according to QUADAS) and Fig. S1 (Study flow), S2 (QUADAS methodological assessment results), S3 (Sensitivity
and specificity for TP level I patients versus TN at-risk patients), S4 (HSROC curves for the subgroup of studies published
in or after 2000), S5 (TP level I patients versus TN at-risk patients: subgroup of studies using whole blood samples, rRNA,
or p450 target genes, an in vitro detection limit of <10 CFU /ml, and PCR other than Septifast), and S6 (Metaregression of colonization rates on specificity
in the comparison of TP level III patients versus TN at-risk patients)
Zipped MS Word document, 298K.
- Supplemental file 1
-
Tables S1 (QUADAS items assessed, adapted for the current review), S2 (Study characteristics), and S3 and S4 (Study design
and methods according to QUADAS) and Fig. S1 (Study flow), S2 (QUADAS methodological assessment results), S3 (Sensitivity
and specificity for TP level I patients versus TN at-risk patients), S4 (HSROC curves for the subgroup of studies published
in or after 2000), S5 (TP level I patients versus TN at-risk patients: subgroup of studies using whole blood samples, rRNA,
or p450 target genes, an in vitro detection limit of <10 CFU /ml, and PCR other than Septifast), and S6 (Metaregression of colonization rates on specificity
in the comparison of TP level III patients versus TN at-risk patients)
